GlassScriptPhysician profile
Weiyun Z Ai
NPI 1649346842
$36,649.26
in general payments reported to CMS, 2019-2025
20 companies · $5,038 in 2025
The $5,038 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $3,615 · 2021: $1,333 · 2022: $4,294 · 2023: $690 · 2024: $7,858 · 2025: $5,038.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $1,484 · Travel and Lodging: $1,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,716.40 |
| Food and Beverage | $1,483.98 |
| Travel and Lodging | $1,385.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $13,851.29 | 2019-2023 | Poteligeo |
| Acrotech Biopharma INC. | $5,805.31 | 2021-2025 | Beleodaq |
| Abbvie INC. | $3,850.03 | 2023-2025 | Venclexta |
| Gilead Sciences, INC. | $3,050.00 | 2024 | |
| Seagen INC. | $2,886.09 | 2019-2022 | |
| Beigene USA, INC. | $1,950.00 | 2020 | |
| Aurobindo Pharma USA, INC. | $1,665.00 | 2020 | |
| Secura Bio, INC. | $1,500.00 | 2022 | |
| Kite Pharma, INC. | $1,299.99 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $387.27 | 2023 | Calquence |
| Adc Therapeutics America, INC. | $212.54 | 2024-2025 | |
| Pfizer INC. | $82.23 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $43.63 | 2021-2023 | Epkinly, Imbruvica |
| Emd Serono, INC. | $41.25 | 2023 | Mavenclad |
| Genmab U.S., INC. | $24.63 | 2023 | Epkinly |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weiyun Ai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.